Cell-based therapies: careful safety assessment for minimization of risk.
Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.
Comoli
Patrizia
P
Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. valentina_comoli@yahoo.it
D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D012308:Risk Management; D017211:Treatment Failure